CANBAS will issue stock acquisition rights through a third-party allotment to SB Securities and raise approximately ¥4.18 billion. The funds are expected to be used for clinical trial expenses and operating expenses, and the issue date is expected to be 30 October.
CANBAS announced that it will issue stock acquisition rights through a third-party allotment, with an option to revise the exercise price. SB Securities will be the allottee. A total of 48,000 units will be issued, representing 4.8 million potential shares. The exercise prices for Series 22 through Series 24 are ¥778, ¥855 and ¥1,010, respectively, with a minimum exercise price of ¥389.
Estimated net proceeds will be ¥4.17564 billion, which will be used for expenses related to the European Phase 3 clinical trial of CBP501 and operating expenses. The maximum dilution ratio relative to the total number of shares issued will be 24.35%.